Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 3, 2011, Pages 596-601

  Narendra Kumar, M ^a   Pavan Kumar, K S R ^a   Jagadeesh Kumar, Vundavilli ^a   John Prasanna, S ^a   Kumar Sharma, Hemant ^a   Krishna Reddy, V ^b  

^a Aurobindo Pharma Limited Research Centre   (India)

^b SRI KRISHNADEVARAYA UNIVERSITY   (India)

Author keywords

3 (N Methylpentylamino)propionic acid; Ibandronate sodium; Ion chromatography; Methanesulfonic acid; Phosphate

Indexed keywords

3 (N METHYLPENTYLAMINO)PROPIONIC ACID; ACETONE; FORMIC ACID; IBANDRONIC ACID; MESYLIC ACID; PHOSPHATE; PHOSPHITE; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CONDUCTOMETRY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG IMPURITY; DRUG STABILITY; ENVIRONMENTAL TEMPERATURE; FLOW RATE; HUMIDITY; HYDROLYSIS; ION PAIR CHROMATOGRAPHY; LINEAR SYSTEM; OXIDATIVE STRESS; PARTICLE SIZE; PHOTOLYSIS; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROCESS OPTIMIZATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THERMOSTABILITY; VALIDATION PROCESS;

CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, REVERSE-PHASE; DIPHOSPHONATES; DRUG CONTAMINATION; DRUG STABILITY; HUMANS; HUMIDITY; HYDROLYSIS; PHOTOLYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TEMPERATURE;

EID: 78149501119     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.026     Document Type: Article

References (9)

1. Bauss F., Lalla S., Endele R., Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical propertites, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol. 2002, 29:2200-2208.
2. Bauss F., Graham G R.R. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos. Int. 2004, 15:423-433.
3. Lovdahl M.J., Pietrzyk D.J. Anion-exchange separation and determination of bisphosphonates and related analytes by post-column indirect fluorescence detection. J. Chromatogr. A 2000, 868:141-142.
4. My H., Xq Z., Bc W. Determination of ibandronate by high performance ion exchange chromatography. Se Pu. 2000, 18:254-255.
5. Rodriguez J.A.B., Desimone M.F., Iglesias S.L., Giorgieri S.A., Diaz L.E. Validation of a capillary electrophoresis method for the analysis of ibandronate related impurities. J. Pharm. Biomed. Anal. 2007, 44:305-308.
6. Jiang Y., Xie Z. Determination of Ibandronate and its degradation products by ion-pair RP LC with evaporative light-scattering detection. Chromatographia 2005, 62:257-261.
7. Zacharis C.K., Tzanavaras P.D. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods. J. Pharm. Biomed. Anal. 2008, 48:483-496.
8. International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, Validation of analytical procedures: text and methodology Q2(R1), step 4 2005.
9. International Conference on Harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, Stability testing of new drug substances and products Q1A(R2), step 4 2003.